Patent · US Active

Compositions and methods for treatment of diabetic macular edema

US10428158B2 · kind B2 · utility

10Cited by

36References

9Claims

0Family size

Assignee

Dyax Corp. · US

Inventors

Gregory P. Conley · Arlington, US
Andrew Nixon · Hanover, US
Daniel J. Sexton · Melrose, US

Key dates

Filing date	Mar 26, 2015
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Apr 29, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.